Sign in
4

Changes in Ownership

Roivant Sciences Ltd. Filed Acc 0001635088-26-000139

CFO sold 300,000 shares at an average $41.58 ($12,473,272)

  • CFO acquired 252,365 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Pulik Richard CFO 2026-11-10 Option exercise +125,000 $3.85 $481,250 394,681 D: show line 1 in the form
Pulik Richard CFO 2026-11-10 Sale −125,000 $41.20 $5,150,000 269,681 D: show line 2 in the form
Pulik Richard CFO 2026-11-11 Option exercise +127,365 $3.85 $490,355 397,046 D: show line 3 in the form
Pulik Richard CFO 2026-11-11 Sale −45,195 $41.47 $1,874,237 351,851 D: show line 4 in the form
Pulik Richard CFO 2026-11-11 Sale −82,170 $42.03 $3,453,605 269,681 D: show line 5 in the form
Pulik Richard CFO 2026-11-11 Sale −47,635 $41.89 $1,995,430 222,046 D: show line 6 in the form
Open-market sales · 300,000 sh · avg $41.58 · $12,473,272

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Pulik Richard CFO 2026-11-10 Option exercise · Stock Option (Right to Buy) −125,000 615,000 D: show line 7 in the form
Pulik Richard CFO 2026-11-11 Option exercise · Stock Option (Right to Buy) −127,365 487,635 D: show line 8 in the form
Loading xslF345X06/wk-form4_1794528063.xml…